All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

  TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer.   View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

EHA 2018 | Atezolizumab plus R-CHOP in previously untreated DLBCL

By Sara Valente

Share:

Jul 18, 2018


On Saturday 16th June an oral abstract session took place at the 23rd congress of the European Hematology Association (EHA). Abstract S803 was presented by Anas Younes, Memorial Sloan Kettering Cancer Center, New York, US, on the efficacy and safety of atezolizumab plus R-CHOP.

The results of the interim analysis were presented of a phase I/II study on the use of atezolizumab, an anti-PD-L1 antibody, in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) (NCT02596971). The primary endpoint was complete response (CR) by PET-CT and safety. The secondary endpoints were objective response rate (ORR), duration of response (DOR) and progression-free survival (PFS) by investigator assessment and MRD.

Study Overview

  • 42 patients were inducted and included in the interim safety analysis and 15 patients completed the induction and were included in the interim efficacy analysis
  • The ORR at the end of induction (n = 15), was 87% as per the modified Lugano 2014 and Cheson 2007 by both the independent review committee and investigator assessment
  • MRD was evaluated at 10-5 sensitivity using Adaptive ImmunoSEQ® NGS platform (v2). 15 patient samples were collected at baseline and it was found that 5 patients were MRD negative at the end of induction
  • At induction, adverse events (AEs) Grade 3-4 occurred in 64% and at consolidation Grade 3-4 AEs occurred in 15%

Dr Younes concluded that at the interim analysis, R-CHOP with atezolizumab showed encouraging activity in patients with previously untreated DLBCL with a manageable safety profile.

References

Your opinion matters

Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?